CXCR4 as biomarker for radioresistant cancer stem cells

International Journal of Radiation Biology

Volumn 90, Issue 8, 2014, Pages 687-699

  Trautmann, Franziska ^a   Cojoc, Monica ^a   Kurth, Ina ^a   Melin, Nicolas ^d   Bouchez, Laure C ^c   Dubrovska, Anna ^a,b   Peitzsch, Claudia ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biomarker; Cancer stem cells; Radioresistance; Radiotherapy

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; EXPERIENCE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOXIA; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; RADIOSENSITIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

BIOMARKER; CANCER STEM CELLS; RADIORESISTANCE; RADIOTHERAPY;

ANIMALS; HUMANS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84905404344     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2014.906766     Document Type: Article

References (169)

1. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. 2011. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest 40: 447-464.
2. Ablett MP, OBrien CS, Sims AH, Farnie G, Clarke RB. 2013. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget 5: 599-612.
3. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. 2006. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66: 9054-9064.
4. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. 1997. The chemokine SDF-1 is a chemoattractant for human CD34 + hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34 + progenitors to peripheral blood. J Exp Med 185: 111-120.
5. Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB, Singh AP. 2013. An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through ROS-dependent, NF-κB-and HIF-1 α-mediated upregulation of CXCR4. J Biol Chem 288: 21197-21207.
6. Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al. 2009. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351.
7. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, et al. 2012. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119: 5782-5794.
8. Baccelli I, Trumpp A. 2012. The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
10. Baumann M, Krause M. 2010. CD44: A cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 16: 5091-5093.
11. Baumann M, Krause M, Hill R. 2008. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554.
12. Bhaskara VK, Mohanam I, Rao JS, Mohanam S. 2012. Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One 7: e30905.
13. Brown JM. 2013. Inhibiting vasculogenesis after radiation: A new paradigm to improve local control by radiotherapy. Semin Radiat Oncol 23: 281-287.
14. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, et al. 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201: 1307-1318.
15. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. 2012. Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 22: 151-174.
16. Burger JA, Kipps TJ. 2006. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767.
17. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. 2005. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106: 1824-1830.
18. Burnette B, Weichselbaum RR. 2013. Radiation as an immune modulator . Semin Radiat Oncol 23: 273-280.
19. Burrell K, Hill RP, Zadeh G. 2012. High-resolution in-vivo analysis of normal brain response to cranial irradiation. PLoS One 7: e38366.
20. Bütof R, Dubrovska A, Baumann M. 2013. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 108: 388-396.
21. Cai W-B, Zhang Y, Cheng R, Wang Z, Fang S-H, Xu Z-M, Yang X, Yang Z-H, Ma J-X, Shao C-K, et al. 2012. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1 α pathway. PLoS One 7: e53152.
22. Cairns RA, Hill RP. 2004. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 64: 2054-2061.
23. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
24. Chaffer CL, Weinberg RA. 2011. A perspective on cancer cell metastasis . Science 331: 1559-1564.
25. Chaudary N, Hill RP. 2009. Increased expression of metastasisrelated genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab Invest 89: 587-596.
26. Chaudary N, Mujcic H, Wouters BG, Hill RP 2013. Hypoxia and metastasis in an orthotopic cervix cancer xenograft model. Radiother Oncol. http://dx.doi.org/10.1016/j.radonc.2013.06.019
27. Chen F-H, Fu S-Y, Yang Y-C, Wang C-C, Chiang C-S, Hong J-H. 2013a. Combination of vessel-targeting agents and fractionated radiation therapy: The role of the SDF-1/CXCR4 Pathway. Int J Radiat Oncol 86: 777-784.
28. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. 2013b. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 123: 2395-2407.
29. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, et al. 2013. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152.
30. Chinni SR, Sivalogan S, Dong Z, Filho JCT, Deng X, Bonfil RD, Cher ML. 2006. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. The Prostate 66: 32-48.
31. Choi YH, Burdick MD, Strieter BA, Mehrad B, Strieter RM. 2013. CXCR4, but not CXCR7, discriminates metastatic behavior in nonsmall cell lung cancer cells. Mol Cancer Res 12: 38-47.
32. De Clercq E. 2003. The bicyclam AMD3100 story. Nat Rev Drug Discov 2: 581-587.
33. Cojoc M, Peitzsch Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. 2013. Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. OncoTargets Ther 1347.
34. Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR. 2013. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling . Mol Cancer 12: 85.
35. Cullis PM, Jones GD, Symons MC, Lea JS. 1987. Electron transfer from protein to DNA in irradiated chromatin. Nature 330: 773-774.
36. Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J. 2008. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron 1: 53-68.
37. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
38. Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. 2011. CXCR7/CXCR4 heterodimer constitutively recruits ã -arrestin to enhance cell migration. J Biol Chem 286: 32188-32197.
39. Della Donna L, Lagadec C, Pajonk F. 2012. Radioresistance of prostate cancer cells with low proteasome activity. Prostate 72: 868-874.
40. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Marzio PD, Marmon S, Sutton RE, Hill CM, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
41. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJK, Kliphuis NM, Huls G, De Vries EGE, de Jong IJ, et al. 2012a. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia NY 14: 709-718.
42. Domanska UM, Timmer-Bosscha H, de Vries EGE, Huls G, van Vugt MATM, Walenkamp AME. 2012b. Abstract 1511: CXCR4 inhibition sensitizes prostate cancer cells to radiotherapy in an in vitro co-culture model. Cancer Res 72: 1511-1511.
43. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, Walenkamp AME. 2013. A review on CXCR4/ CXCL12 axis in oncology: No place to hide. Eur J Cancer 49: 219-230.
44. Doranz BJ, Filion LG, Diaz-Mitoma F, Sitar DS, Sahai J, Baribaud F, Orsini MJ, Benovic JL, Cameron W, Doms RW. 2001. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 17: 475-486.
45. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, VandenBerg S, Johnson RS, Werb Z, et al. 2008. HIF1 á induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220.
46. Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, Yan F, Wang Y, Bouchez LC, Kularatne SA, et al. 2012a. CXCR4 expression in prostate cancer progenitor cells. PLoS One 7: e31226.
47. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG. 2012b. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107: 43-52.
48. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. 2011. CXCL12 (SDF1?)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anti-cancer therapies? Clin Cancer Res 17: 2074-2080.
49. Eke I, Cordes N. 2011. Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation. Radiother Oncol 99: 271-278.
50. Eke I, Storch K, Kästner I, Vehlow A, Faethe C, Mueller-Klieser W, Taucher-Scholz G, Temme A, Schackert G, Cordes N. 2012. Threedimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int J Radiat Oncol 84: e515-523.
51. Engl T, Relja B, Marian D, Blumenberg C, Müller I, Beecken W-D, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D, et al. 2006. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8: 290-301.
52. Faber A. 2013. SDF-1-CXCR4 axis: Cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma. Oncol Rep 29: 2325-2331.
53. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, et al. 2012. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg 144: 1167-1175.e1.
54. Fan H, Wong D, Ashton SH, Borg KT, Halushka PV, Cook JA. 2012. Beneficial effect of a CXCR4 agonist in murine models of systemic. Inflammation 35: 130-137.
55. Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. 2012. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol 82: 51-57.
56. Fusi A, Liu Z, Kümmerlen V, Nonnemacher A, Jeske J, Keilholz U. 2012. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 10: 52.
57. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. 2002. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680-687.
58. Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L, Hill RP. 2006. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 80: 132-137.
59. Gao H, Priebe W, Glod J, Banerjee D. 2009. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells 27: 857-865.
60. Ghisolfi L, Keates AC, Hu X, Lee D, Li CJ. 2012. Ionizing radiation induces stemness in cancer cells. PLoS One 7: e43628.
61. Ghosh S, Kumar A, Tripathi RP, Chandna S. 2013. Connexin-43 regulates p38-mediated cell migration and invasion induced selectively in tumour cells by low doses of ã -radiation in an ERK-1/2-independent manner. Carcinogenesis bg t 303.
62. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49: 24S-42S.
63. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
64. Gourni E, Demmer O, Schottelius M, DAlessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester H-J. 2011. PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent. J Nucl Med 52: 1803-1810.
65. Gros SJ, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Effenberger K, Reichelt U, Hoffman RM, Pantel K, Kaifi JT, et al. 2012. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One 7: e47287.
66. Gupta T, Nair V, Paul SN, Kannan S, Moiyadi A, Epari S, Jalali R. 2012. Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma? J Neurooncol 109: 195-203.
67. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
68. Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold MET, Schall TJ, Mentlein R. 2010. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 70: 3299-3308.
69. Heckmann D, Maier P, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Allgayer H. 2013. CXCR4 expression and treatment with SDF-1? or plerixafor modulate proliferation and chemosensitivity of colon cancer cells. Transl Oncol 6: 124-132.
70. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. 2010. Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795.
71. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
72. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34: 70-74.
73. Hill RP, Milas L. 1989. The proportion of stem cells in murine tumors. Int J Radiat Oncol 16: 513-518.
74. Hill RP, Marie-Egyptienne DT, Hedley DW. 2009. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19: 106-111.
75. Höckel M, Vaupel P. 2001. Tumor hypoxia: Definitions and current clinical, biologic, molecular aspects. J Natl Cancer Inst 93: 266-276.
76. Huber SM, Butz L, Stegen B, Klumpp D, Braun N, Ruth P, Eckert F. 2013. Ionizing radiation, ion transports, radioresistance of cancer cells. Front Physiol 4.
77. Imaizumi N, Monnier Y, Hegi M, Mirimanoff R-O, Rüegg C. 2010. Radiotherapy suppresses angiogenesis in mice through TGF-ã RI/ ALK5-dependent inhibition of endothelial cell sprouting. PLoS One 5: e11084.
78. Jin DK, Shido K, Kopp H-G, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, et al. 2006. Cytokinemediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12: 557-567.
79. Jung M-J, Rho J-K, Kim Y-M, Jung JE, Jin YB, Ko Y-G, Lee J-S, Lee S-J, Lee JC, Park M-J. 2012. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32: 209-221.
80. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. 2005. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97: 1840-1847.
81. Karin N. 2010. The multiple faces of CXCL12 (SDF-1 á ) in the regulation of immunity during health and disease. J Leukoc Biol 88: 463-473.
82. Kavsak PA, Henderson M, Moretto P, Hirte H, Evans K, Wong D, Korz W, Hotte SJ. 2009. Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel antimetastasis agent. Clin Biochem 42: 1162-1165.
83. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. 2010. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120: 694-705.
84. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. 2010. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 70: 5679-5685.
85. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. 2011. Cancer stem cells: Targets and potential biomarkers for radiotherapy. Clin Cancer Res 17: 7224-7229.
86. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ. 2004. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35: 233-245.
87. Kuonen F, Secondini C, Rüegg C. 2012. Molecular pathways: Emerging pathways mediating growth, invasion, metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 18: 5196-5202.
88. Lagadec C, Vlashi E, Donna LD, Meng Y, Dekmezian C, Kim K, Pajonk F. 2010. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 12: R13.
89. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. 2012. Radiation-induced reprogramming of breast cancer cells. Stem Cells 30: 833-844.
90. Lagadec C, Vlashi E, Alhiyari Y, Phillips TM, Bochkur Dratver M, Pajonk F. 2013. Radiation-induced notch signaling in breast cancer stem cells. Int J Radiat Oncol 87: 609-618.
91. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. 2009. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113: 6085-6093.
92. Li Z, Rich JN. 2010. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. In: Simon, MC, editor. Diverse effects of hypoxia on tumor progression. New York: Springer Berlin Heidelberg; pp. 21-30.
93. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, Wang Z. 2012. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 322: 169-176.
94. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, et al. 2004. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469.
95. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. 2004. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64: 4302-4308.
96. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, et al. 2002. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, adhesion Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL, December 7-11, 2001. Blood 100: 2597-2606.
97. Liu Z, Habener JF. 2009. Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 52: 1589-1598.
98. Liu X, Zhou C, Li Y, Ji Y, Xu G, Wang X, Yan J. 2013. SDF-1 promotes endochondral bone repair during fracture healing at the traumatic brain injury condition. PLoS One 8: e54077.
99. Lu M, Grove EA, Miller RJ. 2002. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci USA 99: 7090-7095.
100. Lumniczky K, Sáfrány G 2013. The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences. Cancer Lett. http://dx.doi.org/10.1016/j.canlet.2013.08.024
101. Luo J, Ok Lee S, Liang L, Huang C-K, Li L, Wen S, Chang C. 2013. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. doi: 10.1038/onc.2013.233
102. Luo Y, Cai J, Xue H, Mattson MP, Rao MS. 2006. SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. Neurosci Lett 398: 291-295.
103. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA. 1998. Impaired B-lymphopoiesis, myelopoiesis, derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 95: 9448-9453.
104. Mäbert k, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A,. 2014. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 90: 659-677.
105. Malanchi I, Santamaria-Mart í nez A, Susanto E, Peng H, Lehr H-A, Delaloye J-F, Huelsken J. 2012. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-89.
106. Malik R, Marchese A. 2010. Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Mol Biol Cell 21: 2529-2541.
107. Marchese A, Benovic JL. 2001. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 276: 45509-45512.
108. Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL. 2003. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell 5: 709-722.
109. Meijer TWH, Kaanders JHAM, Span PN, Bussink J. 2012. Targeting hypoxia, HIF-1, tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18: 5585-5594.
110. Mihatsch J, Toulany M, Bareiss PM, Grimm S, Lengerke C, Kehlbach R, Rodemann HP. 2011. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol 99: 300-306.
111. Milas L, Hittelman WN. 2009. Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol 19: 96-105.
112. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle J-C, Ciarloni L, Rejevic-Blant S, Moeckli R, et al. 2008. CYR61 and αV ã 5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323-7331.
113. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
114. Ok S, Kim S-M, Kim C, Nam D, Shim BS, Kim S-H, Ahn KS, Choi S-H, Ahn KS. 2012. Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacol Immunotoxicol 34: 768-778.
115. Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, San H, Childs R, Kovacic JC, Boehm M. 2008. p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest 118: 2050-2061.
116. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011.
117. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
118. Paget S. 1889. The distribution of secondary growths in cancer of the breast. Lancet 133: 571-573.
119. Pajonk F, Vlashi E. 2013. Characterization of the stem cell niche and its importance in radiobiological response. Semin Radiat Oncol 23: 237-241.
120. Pajonk F, Vlashi E, McBride WH. 2010. Radiation resistance of cancer stem cells: The 4 R s of radiobiology revisited. Stem Cells 28: 639-648.
121. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. 2013. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol J Eur Soc Ther Radiol Oncol 108: 378-387.
122. Peitzsch C, Perrin RL, Hill RP, Dubrovska A, Kurth I. 2014. Hypoxia as a Biomarker for Radioresistant Cancer Stem Cells. Int. J. Radiat. Biol.
123. Phillips TM, McBride WH, Pajonk F. 2006. The response of CD24(-/ low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
124. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, et al. 2012. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7: e33788.
125. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. 2006. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20: 1915-1924.
126. Rettig MP, Ansstas G, DiPersio JF. 2012. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 26: 34-53.
127. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. 2004. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia NY 6: 1-6.
128. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. 2007. Oncomine 3.0: Genes, pathways, networks in a collection of 18,000 cancer gene expression profiles. Neoplasia NY 9: 166-180.
129. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. 2009. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21: 761-767.
130. Saha B, Peron S, Murray K, Jaber M, Gaillard A. 2013. Cortical lesion stimulates adult subventricular zone neural progenitor cell proliferation and migration to the site of injury. Stem Cell Res 11: 965-977.
131. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, et al. 2003. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402.
132. Schofield R. 1978. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4: 7-25.
133. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298-1312.
134. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432: 396-401.
135. Sison EAR, Rau RE, McIntyre E, Li L, Small D, Brown P. 2013. MLLrearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol 160: 785-797.
136. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper B-A, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, et al. 2008. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8: 4521-4533.
137. Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, Carvalho LM, Rüegg C, Grillo IM, Barata JT, et al. 2010. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 5: e11222.
138. Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, van de Velde CJH, van Vlierberghe RL, Morreau H, Tollenaar RA, Kuppen PJK. 2008. Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron 2: 1-7.
139. Su W, Chen Y, Zeng W, Liu W, Sun H. 2012. Involvement of Wnt signaling in the injury of murine mesenchymal stem cells exposed to X-radiation. Int J Radiat Biol 88: 635-641.
140. Tabatabai G, Frank B, Möhle R, Weller M, Wick W. 2006. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-ã -dependent HIF-1 á -mediated induction of CXCL12. Brain 129: 2426-2435.
141. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al. 1998. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393: 591-594.
142. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
143. Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, Trent JO, Nakashima H, Yamamoto N, Peiper SC, et al. 2005. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 48: 3280-3289.
144. Tamamura H, Tsutsumi H, Masuno H, Mizokami S, Hiramatsu K, Wang Z, Trent JO, Nakashima H, Yamamoto N, Peiper SC, et al. 2006. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org Biomol Chem 4: 2354-2357.
145. Tang DG. 2012. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22: 457-472.
146. Teicher BA, Fricker SP. 2010. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931.
147. Trent JO, Wang Z, Murray JL, Shao W, Tamamura H, Fujii N, Peiper SC. 2003. Lipid bilayer simulations of cxcr4 with inverse agonists and weak partial agonists. J Biol Chem 278: 47136-47144.
148. Tseng D, Vasquez-Medrano DA, Brown JM. 2011. Targeting SDF-1/ CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer 104: 1805-1809.
149. Ueda S, Oishi S, Wang Z, Araki T, Tamamura H, Cluzeau J, Ohno H, Kusano S, Nakashima H, Trent JO, et al. 2007. Structure-activity relationships of cyclic peptide-based chemokine receptor cxcr4 antagonists: Disclosing the importance of side-chain and backbone functionalities. J Med Chem 50: 192-198.
150. Uy GL, Rettig MP, Cashen AF. 2008. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther 8: 1797-1804.
151. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, et al. 2012. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia . Blood 119: 3917-3924.
152. Viola A, Luster AD. 2008. Chemokines and their receptors: Drug targets in immunity and inflammation. Ann Rev Pharmacol Toxicol 48: 171-197.
153. Visvader JE, Lindeman GJ. 2012. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 10: 717-728.
154. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. 2008. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: 927-936.
155. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang X-F, White RR, Rich JN, Sullenger BA. 2010a. Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28.
156. Wang S-C, Lin J-K, Wang H-S, Yang S-H, Li AF-Y, Chang S-C. 2010b. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 25: 1185-1191.
157. Wiesner C, Bonfil RD, Dong Z, Yamamoto H, Nabha SM, Meng H, Saliganan A, Sabbota A, Cher ML. 2007. Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. Urology 69: 795-799.
158. Withers HR. 1975. Cell cycle redistribution as a factor in multifraction irradiation. Radiology 114: 199-202.
159. Woodard LE, Nimmagadda S. 2011. CXCR4-based imaging agents. J Nucl Med 52: 1665-1669.
160. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. 2007. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104: 618-623.
161. Xu L, Duda DG, Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin P-C, et al. 2009. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1 α , CXCR4, CXCL6, Neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69: 7905-7910.
162. Yan S, Wang Y, Yang Q, Li X, Kong X, Zhang N, Yuan C, Yang N, Kong B.. 2013. Low-dose radiation-induced epithelial-mesenchymal transition through NF-# B in cervical cancer cells. Int J Oncol 42: 1801-1806.
163. Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Tomita S, Ichikawa K, Imura J, Hiraishi H, Fujimori T. 2008. Expression of SDF-1 α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 98: 1682-1689.
164. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW. 2006. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion. Lab Invest 86: 1221-1232.
165. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, Feng X, et al. 2013. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1 á in hepatocellular carcinoma. BMC Cancer 13: 108.
166. Zhang S, Han Z, Jing Y, Tao S, Li T, Wang H, Wang Y, Li R, Yang Y, Zhao X, et al. 2012. CD133+ CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 10: 85.
167. Zhou W, Dosey TL, Biechele T, Moon RT, Horwitz MS, Ruohola-Baker H. 2011. Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct. PLoS One 6: e27460.
168. Zhuo W, Jia L, Song N, Lu X, Ding Y, Wang X, Song X, Fu Y, Luo Y. 2012. The CXCL12-CXCR4 chemokine pathway: A novel axis regulates lymphangiogenesis. Clin Cancer Res 18: 5387-5398.
169. Zou Y-R, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595-599.